Avet Pharmaceuticals Inc. announced FDA approval of its Abbreviated New Drug Application for oral acyclovir, potentially strengthening its position in the generic antiviral market. This approval provides a cost-effective alternative to branded therapeutics, creating opportunities to capture market share in the oral antiviral segment.